Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?

PDGF receptor mutations in human diseases

(2021) Emilie Guérit et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Next-Generation Immunotherapies to Improve Anticancer Immunity

(2021) Yaoyao Shi et al.   Frontiers in Pharmacology

Biphenylurea/thiourea derivatives tagged with heteroarylsulfonamide motifs as novel VEGFR2 inhibitors; Design, synthesis and anti-angiogenic activity

(2021) Ghada H. Al-Ansary et al.   BIOORGANIC CHEMISTRY

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

(2021) Hao Jin et al.   Future Medicinal Chemistry

Unlocking the potential of antibody–drug conjugates for cancer therapy

(2021) Joshua Z. Drago et al.   Nature Reviews Clinical Oncology

Macrophage AXL receptor tyrosine kinase inflames the heart after reperfused myocardial infarction

(2021) Matthew DeBerge et al.   JOURNAL OF CLINICAL INVESTIGATION

Discovery of Potent Carbonic Anhydrase Inhibitors as Effective Anticonvulsant Agents: Drug Design, Synthesis, and In Vitro and In Vivo Investigations

(2021) Chandra Bhushan Mishra et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis and biological evaluation of 2,3-dihydroimidazo[2,1-b]thiazoles as dual EGFR and IGF1R inhibitors

(2021) Pradip K. Gadekar et al.   BIOORGANIC CHEMISTRY

Soluble AXL as a marker of disease progression and survival in melanoma

(2020) Karine Flem-Karlsen et al.   PLoS One

Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non–small cell lung cancer

(2020) Eri Sugiyama et al.   Science Immunology

IGF-1R drugs travel from cancer cradle to Graves’

(2020) Elie Dolgin   NATURE BIOTECHNOLOGY

Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: Where are we today?

(2020) Chandra B. Mishra et al.   MEDICINAL RESEARCH REVIEWS

Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation

(2020) Ibrahim.H. Eissa et al.   BIOORGANIC CHEMISTRY

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity

(2020) Won Suk Lee et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy

(2020) Jimin Yuan et al.   Journal of Hematology & Oncology

Identifying the natural polyphenol catechin as a multi-targeted agent against SARS-CoV-2 for the plausible therapy of COVID-19: an integrated computational approach

(2020) Chandra Bhushan Mishra et al.   BRIEFINGS IN BIOINFORMATICS

Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity

(2020) Huda K. Mahmoud et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Exploring the Role of TRIP-Brs in Human Breast Cancer: An Investigation of Expression, Clinicopathological Significance, and Prognosis

(2020) Raj Kumar Mongre et al.   Molecular Therapy-Oncolytics

Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFRL858R/T790M inhibitors

(2020) Jianheng Li et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Prognostic and Clinicopathological Significance of SERTAD1 in Various Types of Cancer Risk: A Systematic Review and Retrospective Analysis

(2019) Raj Mongre et al.   Cancers

A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer

(2019) Jieun Park et al.   Scientific Reports

VEGF in Signaling and Disease: Beyond Discovery and Development

(2019) Rajendra S. Apte et al.   CELL

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

(2019) Rastilav Bahleda et al.   CLINICAL CANCER RESEARCH

Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer

(2019) Marisa L. Martin-Fernandez et al.   Cells

IL-32γ suppresses lung cancer stem cell growth via inhibition of ITGAV-mediated STAT5 pathway

(2019) Yong Sun Lee et al.   Cell Death & Disease

Platelet‑derived growth factor‑BB promotes proliferation and migration of retinal microvascular pericytes by up‑regulating the expression of C‑X‑C chemokine receptor types 4

(2019) Dan‑Ni Xiang et al.   Experimental and Therapeutic Medicine

Novel Carbazole-Piperazine Hybrid Small Molecule Induces Apoptosis by Targeting BCL-2 and Inhibits Tumor Progression in Lung Adenocarcinoma in Vitro and Xenograft Mice Model

(2019) Mongre et al.   Cancers

Therapeutic Targeting of the IGF Axis

(2019) Eliot Osher et al.   Cells

Tumor angiogenesis: causes, consequences, challenges and opportunities

(2019) Roberta Lugano et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Homozygous receptors for insulin and not IGF-1 accelerate intimal hyperplasia in insulin resistance and diabetes

(2019) Qian Li et al.   Nature Communications

Discovery of Benzenesulfonamide Derivatives as Carbonic Anhydrase Inhibitors with Effective Anticonvulsant Action: Design, Synthesis, and Pharmacological Evaluation

(2018) Chandra Bhushan Mishra et al.   JOURNAL OF MEDICINAL CHEMISTRY

Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges

(2018) Ramesh Butti et al.   Molecular Cancer

Mechanisms of receptor tyrosine kinase activation in cancer

(2018) Zhenfang Du et al.   Molecular Cancer

Dual roles of endothelial FGF-2–FGFR1–PDGF-BB and perivascular FGF-2–FGFR2–PDGFRβ signaling pathways in tumor vascular remodeling

(2018) Kayoko Hosaka et al.   Cell Discovery

A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children’s Oncology Group phase 1 and pilot consortium trial (ADVL1315)

(2018) James I. Geller et al.   CANCER

Receptor Tyrosine Kinase-Targeted Cancer Therapy

(2018) Toshimitsu Yamaoka et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Fibroblast growth factor receptors as treatment targets in clinical oncology

(2018) Masaru Katoh   Nature Reviews Clinical Oncology

NTRK1 is a positive regulator of YAP oncogenic function

(2018) Xinyuan Yang et al.   ONCOGENE

KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior

(2017) Sejin Jang et al.   HUMAN PATHOLOGY

The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)

(2017) Fatima Ardito et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors

(2017) Ken A. Brameld et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Role of ErbB Receptors in Infection

(2017) Jemima Ho et al.   TRENDS IN MICROBIOLOGY

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status

(2017) Hong Jian et al.   Scientific Reports

Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers

(2017) Helena A. Yu et al.   Journal of the National Comprehensive Cancer Network

Regulation of Ste20-like kinase, SLK, activity: Dimerization and activation segment phosphorylation

(2017) Andrey V. Cybulsky et al.   PLoS One

RAS isoforms and mutations in cancer at a glance

(2016) G. Aaron Hobbs et al.   JOURNAL OF CELL SCIENCE

Mechanisms and regulation of endothelial VEGF receptor signalling

(2016) Michael Simons et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Discovery of pan-VEGF inhibitory peptides directed to the extracellular ligand-binding domains of the VEGF receptors

(2016) J. S. Michaloski et al.   Science Advances

The Contribution of Angiogenesis to the Process of Metastasis

(2015) Diane R. Bielenberg et al.   CANCER JOURNAL

The novel inhibitor BRM270 downregulates tumorigenesis by suppression of NF-κB signaling cascade in MDR-induced stem like cancer-initiating cells

(2015) RAJ KUMAR MONGRE et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective

(2015) Samuel H. Myers et al.   JOURNAL OF MEDICINAL CHEMISTRY

ActivatingPIK3CAMutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer

(2015) Christian D. Young et al.   MOLECULAR & CELLULAR PROTEOMICS

Mechanisms of resistance to EGFR tyrosine kinase inhibitors

(2015) Lihua Huang et al.   Acta Pharmaceutica Sinica B

Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy

(2014) Jennifer Wu et al.   CANCER AND METASTASIS REVIEWS

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)

(2014) T. Dragovich et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805)

(2014) Qing Zhou et al.   LUNG CANCER

Insulin Receptor Signaling in Normal and Insulin-Resistant States

(2014) J. Boucher et al.   Cold Spring Harbor Perspectives in Biology

Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing

(2014) Swee Seong Wong et al.   Nature Communications

Design, Synthesis and Biological Evaluation of Pazopanib Derivatives as Antitumor Agents

(2013) Yuping Jia et al.   Chemical Biology & Drug Design

Microenvironmental regulation of tumor progression and metastasis

(2013) Daniela F Quail et al.   NATURE MEDICINE

Therapeutic targeting of EPH receptors and their ligands

(2013) Andrew W. Boyd et al.   NATURE REVIEWS DRUG DISCOVERY

A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy

(2012) K. H. Baumann et al.   ANNALS OF ONCOLOGY

Platelet-derived growth factors and their receptors: Structural and functional perspectives

(2012) Po-Han Chen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

RET, ROS1 and ALK fusions in lung cancer

(2012) Kengo Takeuchi et al.   NATURE MEDICINE

Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors

(2012) Damien Kee et al.   Therapeutic Advances in Medical Oncology

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer

(2011) Charlotte M Huijts et al.   BMC CANCER

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy

(2010) Gang Niu et al.   CURRENT DRUG TARGETS

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

(2009) Kristy J. Gotink et al.   ANGIOGENESIS

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

(2009) J. M. Carboni et al.   MOLECULAR CANCER THERAPEUTICS

An overview of small-molecule inhibitors of VEGFR signaling

(2009) S. Percy Ivy et al.   Nature Reviews Clinical Oncology

Structure-Based View of Epidermal Growth Factor Receptor Regulation

(2008) Kathryn M. Ferguson   Annual Review of Biophysics

The epidermal growth factor receptor family: Biology driving targeted therapeutics

(2008) M. J. Wieduwilt et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer

(2008) Amit Kumar et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor†

(2008) Philip A. Harris et al.   JOURNAL OF MEDICINAL CHEMISTRY

Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy

(2007) Rongshi Li et al.   MEDICINAL RESEARCH REVIEWS